LEXINGTON, Mass.--(BUSINESS WIRE)--Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that primary and secondary objectives were successfully met in a first-in-human Phase 1b clinical trial of AVX-470, an oral anti-TNF bovine polyclonal antibody, in patients with active ulcerative colitis. he primary objective of the trial was to evaluate the safety and tolerability of AVX-470. No treatment-related serious adverse events (SAEs) were observed, and there were no allergic reactions or opportunistic infections.
Help employers find you! Check out all the jobs and post your resume.
